clofibric acid has been researched along with Dunnigan Syndrome in 1 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sleilati, GG | 1 |
| Leff, T | 1 |
| Bonnett, JW | 1 |
| Hegele, RA | 1 |
1 other study available for clofibric acid and Dunnigan Syndrome
| Article | Year |
|---|---|
Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome.
Topics: Adult; Clofibric Acid; Female; Humans; Hypoglycemic Agents; Insulin; Lipodystrophy, Familial Partial | 2007 |